image credit- shutterstock
China-based startup Huahui Health has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy.
Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialisation of HH160 worldwide.
Pursuant to the agreement, BeOne Medicines will pay Huahui Health an upfront payment of $20 million. Upon exercise of the option by BeOne Medicines, Huahui Health will be entitled to receive an additional $100 million option exercise payment.
Subject to the achievement of development, regulatory and sales milestones, Huahui Health is eligible to receive milestone payments of up to $1.9 billion in milestone payments, as well as tiered royalties on net sales. The parties have also agreed to maintain discussions regarding BeOne Medicines' potential participation in Huahui Health's future financing activities, with specific transaction terms and details to be negotiated separately.
HH160 is a novel trispecific antibody developed by Huahui Health using its proprietary PolyBoost™ multispecific antibody platform. HH160 simultaneously targets PD-1, CTLA-4, and VEGF-A, three clinically validated targets in cancer immunotherapy and anti-angiogenesis. Through its "three-in-one" synergistic mechanism of action, HH160 is expected to enhance therapeutic efficacy, achieve tumor-specific drug distribution, and reduce treatment-related adverse effects.
